ArticleAlzheimer's research & therapy2016
The societal costs of dementia in Sweden 2012 - relevance and methodological challenges in valuing informal care.
Article in Alzheimer's research & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The economic burden of dementia in low- and middle-income countries (LMICs): a systematic review.BMJ global health · 2022Pooled it
- Support, Monitoring, and Reminder Technology for Mild Dementia (SMART4MD) for People With Mild Cognitive Impairment and Their Informal Caregivers: Cost-Effectiveness Analysis.JMIR human factors · 2026Trial
- Short Term Economic Evaluation of the Digital Platform "Support, Monitoring and Reminder Technology for Mild Dementia" (SMART4MD) for People with Mild Cognitive Impairment and their Informal Caregivers.Journal of Alzheimer's disease : JAD · 2022Trial
- The formal care costs of dementia: a longitudinal study using Swedish register data.The European journal of health economics : HEPAC : health economics in prevention and care · 2025Article
- Costs of Care in Relation to Alzheimer's Disease Severity in Sweden: A National Registry-Based Cohort Study.PharmacoEconomics · 2025Article
- Projected costs of informal care for older people in England.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- Rheumatic and Musculoskeletal Diseases and Risk of Dementia: A Nested Case-Control Study.ACR open rheumatology · 2024Article
- Erratum to: Short Term Economic Evaluation of the Digital Platform "Support, Monitoring and Reminder Technology for Mild Dementia" (SMART4MD) for People with Mild Cognitive Impairment and Their Informal Caregivers.Journal of Alzheimer's disease : JAD · 2024Article
- Functioning and Disability in Community-Living People with Perceived Cognitive Impairment or Dementia: A Mixed Methods Study using the World Health Organization Disability Assessment Schedule.Journal of rehabilitation medicine · 2023Article
- Patterns of long-term care utilization during the last five years of life among Swedish older adults with and without dementia.PloS one · 2023Article
- The Impact of Educational Attainment and Income on Long-Term Care for Persons with Alzheimer's Disease and Other Dementias: A Swedish Nationwide Study.Journal of Alzheimer's disease : JAD · 2023Article
- Health Care Resource Use and Social Costs in Mild Cognitive Impairment and Mild Alzheimer's Disease.Journal of Alzheimer's disease reports · 2023Article
- Long-term care use among people living with dementia: a retrospective register-based study from Sweden.BMC geriatrics · 2022Article
- Healthcare costs of dementia diseases before, during and after diagnosis: Longitudinal analysis of 17 years of Swedish register data.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
- High risk of developing dementia in Parkinson's disease: a Swedish registry-based study.Scientific reports · 2022Article
- Cost analysis of informal care: estimates from a national cross-sectional survey in Sweden.BMC health services research · 2021Article
- Total cost of care increases significantly from early to mild Alzheimer's disease: 5-year ALSOVA follow-up.Age and ageing · 2021Article
- Article
- Socioeconomic Costs of Dementia Based on Utilization of Health Care and Long-Term-Care Services: A Retrospective Cohort Study.International journal of environmental research and public health · 2021Article
- Exploring costs, cost components, and associated factors among people with dementia approaching the end of life: A systematic review.Alzheimer's & dementia (New York, N. Y.) · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn this study, we sought to estimate the societal cost of illness in dementia in Sweden in 2012 using different costing approaches to highlight methodological issues.
methodsWe conducted a prevalence-based cost-of-illness study with a societal perspective.
resultsThe societal costs of dementia in Sweden in 2012 were SEK 62.9 billion (approximately €7.2 billion, approximately US$9.0 billion) or SEK 398,000 per person with dementia (approximately €45,000, approximately US$57,000). By far the most important cost item is the cost of institutional care: about 60% of the costs. In the sensitivity analysis, different quantification and costing approaches for informal care resulted in a great variation in the total societal cost, ranging from SEK 60 billion (€6.8 billion, US$8.6 billion) to SEK 124 billion (€14.1 billion, US$17.8 billion).
conclusionsThe societal costs of dementia are very high. The cost per person with dementia has decreased somewhat, mainly because of de-institutionalisation. The majority of the costs occur in the social care sector, but the costing of informal care is crucial for the cost estimates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.